StonvexLoading…
StonvexStonvexStonvexCore line items from RXO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $5.74B | $4.55B | $3.93B | $4.80B |
Operating Income | $-79.00M | $-56.00M | $39.00M | $123.00M |
Net Income | $-100.00M | $-290.00M | $4.00M | $92.00M |
EPS (Diluted) | $-0.59 | $-2.17 | $0.03 | $0.79 |
Total Assets | $3.28B | $3.41B | $1.82B | $2.03B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $17.00M | $35.00M | $5.00M | $98.00M |
Free Cash Flow OCF − CapEx | $-8.00M | $-57.00M | $25.00M | $253.00M |
Shares Outstanding | 164.16M | 162.52M | 117.03M | 116.40M |